Company Idorsia Ltd

Equities

IDIA

CH0363463438

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per region

Ratings for Idorsia Ltd

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Swiss Exchange Other stock markets 05:33:01 2024-05-28 am EDT			5-day change	1st Jan Change
2.32 ^CHF	+1.75%		+6.62%	+9.74%

May. 21	Idorsia Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
May. 21	Swiss Stocks Flash Red Amid Economic Data Focus in Europe	MT

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Number of employees: 650

CHF in Million	2022	Weight	2023	Weight	Delta
Drugs 100.0 %	97	100.0 %	152	100.0 %	+56.93%

CHF in Million	2022	Weight	2023	Weight	Delta
Switzerland 57.8 %	47	48.0 %	88	57.8 %	+88.99%
Japan 22.1 %	44	45.3 %	34	22.1 %	-23.45%
United States 16.0 %	6	5.7 %	24	16.0 %	+340.36%
Rest of World 4.1 %	1	1.0 %	6	4.1 %	+525.90%

Managers	Title	Age	Since
Jean-Paul Clozel CEO	Chief Executive Officer	69	17-05-31
André Muller DFI	Director of Finance/CFO	60	17-05-31
Martine Clozel CTO	Chief Tech/Sci/R&D Officer	68	17-05-31
Andrew C. Weiss IRC	Investor Relations Contact	55	17-05-31
Alberto Gimona PRN	Corporate Officer/Principal	64	19-01-31
Julien Gander LAW	General Counsel	45	-
Alexander Khatuntsev HRO	Human Resources Officer	45	17-05-31
Simon Jose PRN	Corporate Officer/Principal	58	18-11-30

Members of the board	Title	Age	Since
Jörn Aldag BRD	Director/Board Member	65	20-05-12
Peter Kellogg BRD	Director/Board Member	67	21-05-11
Jean-Paul Clozel CEO	Chief Executive Officer	69	17-05-31
Felix R. Ehrat BRD	Director/Board Member	67	20-05-12
Sandy Mahatme BRD	Director/Board Member	59	20-05-12
Mathieu Simon CHM	Chairman	68	19-05-02
Srishti Gupta BRD	Director/Board Member	48	21-05-11
Sophie Kornowski-Bonnet BRD	Director/Board Member	61	23-05-03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	179,784,516	111,025,147 ( 61.75 %)	470,771 ( 0.2619 %)	61.75 %

Name	Equities	%	Valuation
Clozel Family 25.73 %	48,596,772	25.73 %	96 M CHF
JOHNSON & JOHNSON 5.074 %	9,581,882	5.074 %	19 M CHF
IDORSIA LTD 4.792 %	9,049,500	4.792 %	18 M CHF
Rudolf Maag 4.767 %	9,002,083	4.767 %	18 M CHF
Astaris Capital Management LLP 2.587 %	4,885,000	2.587 %	10 M CHF
Rossier, Mari & Associates AG 0.5560 %	1,050,000	0.5560 %	2 M CHF
Banque Cantonale de Genève (Investment Management) 0.4160 %	785,560	0.4160 %	2 M CHF
Finreon AG 0.2126 %	401,513	0.2126 %	792 386 CHF
Mirabaud Asset Management (Suisse) SA 0.1638 %	309,411	0.1638 %	610 623 CHF
Storebrand Asset Management AS 0.1501 %	283,415	0.1501 %	559 320 CHF

Name	Equities	%	Valuation
IDORSIA LTD 4.79%	9,049,500	4.79%	17,859,188 $
SANTHERA PHARMACEUTICALS HOLDING AG 10.31%	1,301,128	10.31%	13,136,826 $

Idorsia Ltd.

Hegenheimermattweg 91

4123, Allschwil

+41 58 844 10 10

http://www.idorsia.com

Name	Category and Sector
Idorsia Pharmaceuticals Ltd. Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017.	Pharmaceuticals: Major

Name

Category and Sector

Pharmaceuticals: Major

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

2.28 CHF

Average target price

1.692 CHF

Spread / Average Target

-25.77%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
IDORSIA LTD	+9.74%	447M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.22%	22.1B
GENMAB A/S	-8.33%	18.34B
WUXI APPTEC CO., LTD.	-41.70%	16.59B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs